ELIZABETH D FERUCCI MD
Prescription History 1598705121
Internal Medicine - Rheumatology in Anchorage, AK


Quality Rating: 87.09 out of 100 score

NPI Status: Active since June 08, 2006

Contact Information

4315 DIPLOMACY DR
ANCHORAGE, AK
ZIP 99508
Phone: (907) 729-1500
Fax: (907) 729-2082

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for ELIZABETH D FERUCCI MD, an active Rheumatology specialist practicing in Anchorage, AK. Our medical registry currently tracks 5 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 129 documented patient claims. Among these therapy options, the most frequently utilized medication is Methotrexate, which accounts for 49 claims alone.

Medication Index


Humira(Cf) Pen

Generic Formulation: AdalimumabSpecialty: Rheumatology
Provider Metrics Summary
Total Claims 33
30-Day Fills 39.2
Days Supply 1,042
AK State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills32.1
Peer Average Days Supply903
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 26.9% more claims than the standard regional baseline profile for AK. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $309,182.61 across this reporting matrix range.

Provider Avg Cost Per Claim

$9,369.17

State Avg Cost Per Claim

$9,639.26

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A humanized monoclonal antibody that binds specifically to TNF-ALPHA and blocks its interaction with endogenous TNF RECEPTORS to modulate INFLAMMATION. It is used in the treatment of RHEUMATOID ARTHRITIS; PSORIATIC ARTHRITIS; CROHN'S DISEASE and ULCERATIVE COLITIS.

Therapeutic Applications

Adalimumab is used to reduce pain and swelling due to certain types of arthritis (such as rheumatoid, psoriatic, juvenile idiopathic, ankylosing spondylitis). This medication is also used to treat certain skin disorders (such as plaque-type psoriasis, hidradenitis suppurativa). It works by blocking a protein (tumor necrosis factor or TNF) found in the body's immune system that causes joint swelling and damage in arthritis as well as red scaly patches in psoriasis. Adalimumab belongs to a class of drugs known as TNF blockers. By reducing joint swelling, this medication helps to reduce further joint damage and preserve joint function. Adalimumab is also used to treat certain bowel conditions (Crohn's disease, ulcerative colitis) and a certain eye disease (uveitis).

Hydroxychloroquine Sulfate

Generic Formulation: Hydroxychloroquine SulfateSpecialty: Rheumatology
Provider Metrics Summary
Total Claims 21
30-Day Fills 29.0
Days Supply 850
AK State Average Benchmarks
Peer Average Claims40.0
Peer Average 30-Day Fills79.4
Peer Average Days Supply2,275
Conservative Utilization

This provider writes prescriptions for this formulation 47.5% less frequently than the standard regional baseline metric for practitioners inside AK. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,004.56 across this reporting matrix range.

Provider Avg Cost Per Claim

$95.46

State Avg Cost Per Claim

$74.99

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)

Therapeutic Applications

Hydroxychloroquine is used to prevent or treat malaria caused by mosquito bites. The United States Center for Disease Control provides updated guidelines and travel recommendations for the prevention and treatment of malaria in different parts of the world. Discuss the most recent information with your doctor before traveling to areas where malaria occurs. This medication is also used to treat certain auto-immune diseases (lupus, rheumatoid arthritis). It belongs to a class of medications known as disease-modifying antirheumatic drugs (DMARDs). It can reduce skin problems in lupus and prevent swelling/pain in arthritis. Hydroxychloroquine is not recommended for coronavirus infection, also known as COVID-19, unless you are enrolled in a study. Talk to your doctor about the risks and benefits.

Leflunomide

Generic Formulation: LeflunomideSpecialty: Rheumatology
Provider Metrics Summary
Total Claims 11
30-Day Fills 15.0
Days Supply 430
AK State Average Benchmarks
Peer Average Claims30.0
Peer Average 30-Day Fills59.5
Peer Average Days Supply1,711
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 63.3% less volume than the regional standard for practitioners inside AK. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $487.48 across this reporting matrix range.

Provider Avg Cost Per Claim

$44.32

State Avg Cost Per Claim

$87.44

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.

Therapeutic Applications

This medication is used to treat rheumatoid arthritis, a condition in which the body's defense system (immune system) fails to recognize the body as itself and attacks the healthy tissues around the joints. Leflunomide helps to reduce the joint damage/pain/swelling and helps you to move better. It works by weakening your immune system and decreasing swelling (inflammation).

Methotrexate

Generic Formulation: Methotrexate SodiumSpecialty: Rheumatology
Provider Metrics Summary
Total Claims 49
30-Day Fills 67.0
Days Supply 1,957
AK State Average Benchmarks
Peer Average Claims38.0
Peer Average 30-Day Fills71.8
Peer Average Days Supply2,038
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 28.9% more claims than the standard regional baseline profile for AK. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,388.46 across this reporting matrix range.

Provider Avg Cost Per Claim

$48.74

State Avg Cost Per Claim

$44.49

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA.

Therapeutic Applications

Methotrexate is used to treat certain types of cancer (such as acute lymphoblastic leukemia, non-Hodgkin's lymphoma) or to control severe psoriasis or rheumatoid arthritis that has not responded to other treatments. It may also be used to control juvenile rheumatoid arthritis. Methotrexate belongs to a class of drugs known as antimetabolites. It works by slowing or stopping the growth of cancer cells and suppressing the immune system. Early treatment of rheumatoid arthritis with more aggressive therapy such as methotrexate helps to reduce further joint damage and to preserve joint function.

Orencia Clickject

Generic Formulation: AbataceptSpecialty: Rheumatology
Provider Metrics Summary
Total Claims 15
30-Day Fills 15.0
Days Supply 420
AK State Average Benchmarks
Peer Average Claims19.0
Peer Average 30-Day Fills19.0
Peer Average Days Supply532
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across AK. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $83,921.78 across this reporting matrix range.

Provider Avg Cost Per Claim

$5,594.79

State Avg Cost Per Claim

$5,425.52

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A fusion protein immunoconjugate of the extracellular domain of CTLA4 and the Fc domain of human IgG1. It functions as a T-cell co-stimulation blocker that inhibits TNF-ALPHA and prevents the activation of T-LYMPHOCYTES. It is used in the treatment of RHEUMATOID ARTHRITIS.

Therapeutic Applications

This medication is used to treat rheumatoid arthritis, a condition in which the body's own defense system (immune system) attacks healthy tissue. This leads to swelling in the joints, which causes pain and makes it harder to move. Abatacept works by weakening your immune system. This effect helps to slow down joint damage and reduce joint pain and swelling so you can move better. This medication is also used to treat other types of arthritis (such as juvenile idiopathic arthritis, psoriatic arthritis).

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like ELIZABETH D FERUCCI MD provides transparency into local medical care patterns within Anchorage, AK.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Rheumatology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.